missing translation for 'onlineSavingsMsg'
Learn More
  1. Home
  2. Products
  3. Antibodies
  4. Primary Antibodies
  5. All Primary Antibodies
  6. CCL7/MCP-3/MARC Rabbit anti-Human, Clone: 63, Novus Biologicals™
  7. 18248527

CCL7/MCP-3/MARC Rabbit anti-Human, Clone: 63, Novus Biologicals™

Rabbit Monoclonal Antibody

Brand:  Novus Biologicals NBP2-90018-50UL

 View more versions of this product

Product Code. 18248527

  • 367.00 € / 50µL

Please to purchase this item. Need a web account? Register with us today!

This item is not returnable. View return policy

Description

Description

CCL7/MCP-3/MARC Monoclonal specifically detects CCL7/MCP-3/MARC in Human samples. It is validated for ELISA.
TRUSTED_SUSTAINABILITY
Specifications

Specifications

CCL7/MCP-3/MARC
Monoclonal
Unconjugated
0.2 um filtered solution in PBS
Rabbit
Protein A purified
RUO
Primary
Human
Purified
ELISA
63
ELISA 1:5000-1:10000
C-C motif chemokine 7, chemokine (C-C motif) ligand 7, FIC, MARC, MCP3Monocyte chemotactic protein 3, MCP-3Small-inducible cytokine A7, MGC138465, Monocyte chemoattractant protein 3, NC28SCYA6, SCYA7MGC138463, small inducible cytokine A7 (monocyte chemotactic protein 3)
Recombinant Human CCL7/MCP-3/MARC Protein
50 μg
Biologically Active Proteins, Cancer, Chemokines and Cytokines
6354
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
IgG
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.